Early diagnosis of cystic fibrosis through newborn screening can lead to improved height and weight measurements, better pulmonary status, and cognitive benefits. Implementing CF newborn screening in all states aims to give people with this disease the best odds at living longer, healthier lives.
The CF Foundation is leveraging proteomics research to accelerate the discovery of new therapies for cystic fibrosis. By analyzing protein interactions and identifying novel targets, scientists aim to develop effective treatments that can correct faulty cells and prevent disease progression.
A team of researchers has completed the genome sequence of Pseudomonas aeruginosa, the largest bacterium sequenced so far. The findings may lead to innovative therapies for patients with cystic fibrosis and those who develop severe infections.
The Cystic Fibrosis Foundation has selected seven top care centers to participate in an innovative Therapeutics Development Center network. This model will enable researchers to quickly translate laboratory discoveries into new therapies, with the goal of developing life-saving treatments for cystic fibrosis.
A consortium of scientists has released a new genome sequencing project for the bacterium P. aeruginosa, which causes chronic lung infections in CF patients. The project aims to increase practical knowledge about the pathogen and develop new drugs for treatment.